Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 4 single-arm open-label study of Beyfortus in infants and vulnerable young children for RSV prevention
2026-000241-89Phase 4
- Sponsor
- Sanofi
- Start
- Oct 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of nirsevimab in respiratory syncytial virus disease (RSV), sponsored by Sanofi. Primary endpoint: Presence of immediate adverse events.
02
Drugs
nirsevimab
03
Conditions
respiratory syncytial virus disease (RSV)
Beyond the preview
Go deeper on 2026-000241-89.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-000241-89.